Incorrect application of the KDIGO acute kidney injury staging criteria.

Abstract

ABSTRACTBackgroundRecent research demonstrated substantial heterogeneity in the Kidney Disease: Improving Global Outcomes (KDIGO) acute kidney injury (AKI) diagnosis and staging criteria implementations in clinical research. Here we report an additional issue in the implementation of the criteria: the incorrect description and application of a stage 3 serum creatinine (SCr) criterion. Instead of an increase in SCr to or beyond 4.0 mg/dL, studies apparently interpreted this criterion as an increase in SCr by 4.0 mg/dL.MethodsUsing a sample of 8124 consecutive intensive care unit (ICU) admissions, we illustrate the implications of such incorrect application. The AKI stage distributions associated with the correct and incorrect stage 3 SCr criterion implementations were compared, both with and without the stage 3 renal replacement therapy (RRT) criterion. In addition, we compared chronic kidney disease presence, ICU mortality rates and hospital mortality rates associated with each of the AKI stages and the misclassified cases.ResultsWhere incorrect implementation of the SCr stage 3 criterion showed a stage 3 AKI rate of 29%, correct implementation revealed a rate of 34%, mainly due to shifts from stage 1 to stage 3. Without the stage 3 RRT criterion, the stage 3 AKI rates were 9% and 19% after incorrect and correct implementation, respectively. The ICU and hospital mortality rates in cases misclassified as stage 1 or 2 were similar to those in cases correctly classified as stage 1 instead of stage 3.ConclusionsWhile incorrect implementation of the SCr stage 3 criterion has significant consequences for AKI severity epidemiology, consequences for clinical decision making may be less severe. We urge researchers and clinicians to verify their implementation of the AKI staging criteria.